[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible). The item is medically inaccurate and relies on a flawed clinical premise. In a patient with Diamond-Blackfan anemia (DBA) on chronic transfusions presenting with restrictive cardiomyopathy, the overwhelming primary diagnosis is cardiac siderosis (iron overload). The standard of care requires urgent assessment of cardiac iron (e.g., MRI T2*) and aggressive chelation therapy. The keyed answer (D, L-leucine) is an experimental therapy primarily investigated for improving erythropoiesis (anemia) in DBA; there is no established evidence or guideline recommendation supporting its use to reverse severe heart failure or pulmonary hypertension. Suggesting a nutritional supplement as the primary management for life-threatening cardiac decompensation—while ignoring the likely etiology (iron toxicity)—is dangerous. Option E (Cardiac MRI) is the most logical next step to assess iron loading (though T2* is the specific sequence needed), but as written, no option represents appropriate management (chelation/diuretics). Therefore, no defensible best answer exists.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible). The item is medically inaccurate and relies on a flawed clinical premise. In a patient with Diamond-Blackfan anemia (DBA) on chronic transfusions presenting with restrictive cardiomyopathy, the overwhelming primary diagnosis is cardiac siderosis (iron overload). The standard of care requires urgent assessment of cardiac iron (e.g., MRI T2*) and aggressive chelation therapy. The keyed answer (D, L-leucine) is an experimental therapy primarily investigated for improving erythropoiesis (anemia) in DBA; there is no established evidence or guideline recommendation supporting its use to reverse severe heart failure or pulmonary hypertension. Suggesting a nutritional supplement as the primary management for life-threatening cardiac decompensation—while ignoring the likely etiology (iron toxicity)—is dangerous. Option E (Cardiac MRI) is the most logical next step to assess iron loading (though T2* is the specific sequence needed), but as written, no option represents appropriate management (chelation/diuretics). Therefore, no defensible best answer exists.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) and severe preeclampsia with refractory hypertensive emergency. First-line IV agents (labetalol, hydralazine) have failed to control blood pressure. The question asks for the next pharmacologic intervention. Option A (Nitroprusside) is generally avoided due to the risk of fetal cyanide toxicity, reserved only for extreme last-resort scenarios. Option B (Nifedipine XL) specifies an extended-release formulation, which is inappropriate for the acute management of hypertensive crisis (immediate-release would be indicated). Option D (Captopril) is an ACE inhibitor, strictly contraindicated in pregnancy due to fetal renal toxicity and teratogenicity. Option E (Esmolol) carries a risk of fetal bradycardia and is not a standard choice for preeclampsia. Option C (Fenoldopam) is a rapid-acting dopamine-1 agonist that lowers blood pressure and preserves renal perfusion; it is a recognized, safe alternative for refractory hypertension in pregnancy when first-line agents fail or are contraindicated. The item is medically accurate and logically sound, with valid distractors.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) and severe preeclampsia with refractory hypertensive emergency. First-line IV agents (labetalol, hydralazine) have failed to control blood pressure. The question asks for the next pharmacologic intervention. Option A (Nitroprusside) is generally avoided due to the risk of fetal cyanide toxicity, reserved only for extreme last-resort scenarios. Option B (Nifedipine XL) specifies an extended-release formulation, which is inappropriate for the acute management of hypertensive crisis (immediate-release would be indicated). Option D (Captopril) is an ACE inhibitor, strictly contraindicated in pregnancy due to fetal renal toxicity and teratogenicity. Option E (Esmolol) carries a risk of fetal bradycardia and is not a standard choice for preeclampsia. Option C (Fenoldopam) is a rapid-acting dopamine-1 agonist that lowers blood pressure and preserves renal perfusion; it is a recognized, safe alternative for refractory hypertension in pregnancy when first-line agents fail or are contraindicated. The item is medically accurate and logically sound, with valid distractors.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient with Grade 3/4 immune checkpoint inhibitor (ICI) pneumonitis who has failed to improve after 72 hours of high-dose corticosteroids (steroid-refractory). According to major guidelines (ASCO, NCCN, SITC), the standard of care for steroid-refractory ICI pneumonitis is the addition of further immunosuppression. Infliximab (Option A) is the most commonly recommended second-line agent in this setting. Mycophenolate mofetil and IVIG are other potential options, but they are not listed. Cyclophosphamide (Option B) is typically reserved for steroid-refractory ICI myocarditis or as a third-line agent for pneumonitis. Switching corticosteroids (Option C) is unlikely to be effective. Plasma exchange (Option D) is used for ICI-related neurotoxicity, not pneumonitis. Tocilizumab (Option E) is the standard for CAR-T cytokine release syndrome, not ICI pneumonitis. The item is medically accurate, clinically relevant, and presents a clear best answer based on current guidelines.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient with Grade 3/4 immune checkpoint inhibitor (ICI) pneumonitis who has failed to improve after 72 hours of high-dose corticosteroids (steroid-refractory). According to major guidelines (ASCO, NCCN, SITC), the standard of care for steroid-refractory ICI pneumonitis is the addition of further immunosuppression. Infliximab (Option A) is the most commonly recommended second-line agent in this setting. Mycophenolate mofetil and IVIG are other potential options, but they are not listed. Cyclophosphamide (Option B) is typically reserved for steroid-refractory ICI myocarditis or as a third-line agent for pneumonitis. Switching corticosteroids (Option C) is unlikely to be effective. Plasma exchange (Option D) is used for ICI-related neurotoxicity, not pneumonitis. Tocilizumab (Option E) is the standard for CAR-T cytokine release syndrome, not ICI pneumonitis. The item is medically accurate, clinically relevant, and presents a clear best answer based on current guidelines.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette contains a fundamental contradiction that renders the item unsolvable. The physical exam findings of macroglossia, umbilical hernia, and hypoglycemia constitute the classic triad for Beckwith-Wiedemann Syndrome (BWS). However, the laboratory findings of elevated galactose and galactitol are pathognomonic for Galactosemia. These are distinct conditions; Galactosemia does not present with macroglossia, and BWS does not cause galactosemia. The stem conflates features of two unrelated diseases (likely confusing BWS or a Glycogen Storage Disease with Galactosemia). Furthermore, even if one ignores the physical exam and assumes Galactosemia based on the labs, Option D (GALT enzyme deficiency) is the standard gold-standard confirmatory test for Classic Galactosemia. The keyed answer (C) relies on an obscure and non-standard distinction (glycogen content) to differentiate a rare variant (Epimerase deficiency) without any specific clues in the stem to suggest that variant over the classic form. Therefore, the item is medically inaccurate and logically invalid.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette contains a fundamental contradiction that renders the item unsolvable. The physical exam findings of macroglossia, umbilical hernia, and hypoglycemia constitute the classic triad for Beckwith-Wiedemann Syndrome (BWS). However, the laboratory findings of elevated galactose and galactitol are pathognomonic for Galactosemia. These are distinct conditions; Galactosemia does not present with macroglossia, and BWS does not cause galactosemia. The stem conflates features of two unrelated diseases (likely confusing BWS or a Glycogen Storage Disease with Galactosemia). Furthermore, even if one ignores the physical exam and assumes Galactosemia based on the labs, Option D (GALT enzyme deficiency) is the standard gold-standard confirmatory test for Classic Galactosemia. The keyed answer (C) relies on an obscure and non-standard distinction (glycogen content) to differentiate a rare variant (Epimerase deficiency) without any specific clues in the stem to suggest that variant over the classic form. Therefore, the item is medically inaccurate and logically invalid.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with SLE and high-risk APS (triple positive implied by Lupus Anticoagulant and anti-beta2-GPI) who experiences breakthrough venous thrombosis despite therapeutic anticoagulation with warfarin (INR 2.5–3.5). Standard management for breakthrough thrombosis involves verifying adherence, switching to Low Molecular Weight Heparin (LMWH), or increasing the INR target (typically to 3.0–4.0). Option A (Rivaroxaban) is incorrect as DOACs are associated with higher rates of recurrent thrombosis in high-risk APS compared to warfarin (TRAPS trial). Option B (INR 3.5–4.5) suggests a target range higher than the standard high-intensity recommendation (3.0–4.0), significantly increasing bleeding risk without proven benefit. Option D (IVIG) is indicated for Catastrophic APS, not simple DVT. Option E (IVC filter) is reserved for contraindications to anticoagulation. Option C (Add hydroxychloroquine) is the best answer among the choices; EULAR guidelines recommend considering the addition of hydroxychloroquine in refractory APS, particularly in patients with SLE, due to its pleiotropic antithrombotic effects. While switching to LMWH is a primary step often taken (and missing from the options), adding HCQ is a valid and guideline-supported adjunctive strategy for this specific patient profile.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with SLE and high-risk APS (triple positive implied by Lupus Anticoagulant and anti-beta2-GPI) who experiences breakthrough venous thrombosis despite therapeutic anticoagulation with warfarin (INR 2.5–3.5). Standard management for breakthrough thrombosis involves verifying adherence, switching to Low Molecular Weight Heparin (LMWH), or increasing the INR target (typically to 3.0–4.0). Option A (Rivaroxaban) is incorrect as DOACs are associated with higher rates of recurrent thrombosis in high-risk APS compared to warfarin (TRAPS trial). Option B (INR 3.5–4.5) suggests a target range higher than the standard high-intensity recommendation (3.0–4.0), significantly increasing bleeding risk without proven benefit. Option D (IVIG) is indicated for Catastrophic APS, not simple DVT. Option E (IVC filter) is reserved for contraindications to anticoagulation. Option C (Add hydroxychloroquine) is the best answer among the choices; EULAR guidelines recommend considering the addition of hydroxychloroquine in refractory APS, particularly in patients with SLE, due to its pleiotropic antithrombotic effects. While switching to LMWH is a primary step often taken (and missing from the options), adding HCQ is a valid and guideline-supported adjunctive strategy for this specific patient profile.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best\\n\\nThe question asks for the most appropriate antiarrhythmic for a patient with ischemic cardiomyopathy (LVEF 25%) and recurrent VT shocks who cannot tolerate amiodarone. \\n\\nKey stem clues:\\n1. Ischemic CM + LVEF 25%: Contraindicates Class IC agents (Propafenone) due to proarrhythmia (CAST trial) and makes Sotalol dangerous/contraindicated due to increased mortality in post-MI patients with LV dysfunction (SWORD trial).\\n2. Amiodarone intolerance: Eliminates the first-line choice.\\n3. Recurrent VT: Requires effective suppression.\\n\\nEvaluation of options:\\n- Propafenone (E) is absolutely contraindicated in structural heart disease.\\n- Sotalol (B) is generally contraindicated or strongly discouraged in LVEF <30-35% due to negative inotropy and mortality risk in ischemic disease.\\n- Mexiletine (A) is rarely effective as monotherapy for recurrent VT.\\n- Ranolazine (D) is an adjunct, not a primary antiarrhythmic for VT.\\n- Dofetilide (C) is safe in heart failure/ischemic disease (DIAMOND trials). While primarily indicated for AF, it is a recognized second-line option for VT suppression in patients with severe LV dysfunction who cannot take amiodarone or sotalol.\\n\\nThe item is logically sound and medically accurate for board-exam purposes.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best\n\nThe question asks for the most appropriate antiarrhythmic for a patient with ischemic cardiomyopathy (LVEF 25%) and recurrent VT shocks who cannot tolerate amiodarone. \n\nKey stem clues:\n1. Ischemic CM + LVEF 25%: Contraindicates Class IC agents (Propafenone) due to proarrhythmia (CAST trial) and makes Sotalol dangerous/contraindicated due to increased mortality in post-MI patients with LV dysfunction (SWORD trial).\n2. Amiodarone intolerance: Eliminates the first-line choice.\n3. Recurrent VT: Requires effective suppression.\n\nEvaluation of options:\n- Propafenone (E) is absolutely contraindicated in structural heart disease.\n- Sotalol (B) is generally contraindicated or strongly discouraged in LVEF <30-35% due to negative inotropy and mortality risk in ischemic disease.\n- Mexiletine (A) is rarely effective as monotherapy for recurrent VT.\n- Ranolazine (D) is an adjunct, not a primary antiarrhythmic for VT.\n- Dofetilide (C) is safe in heart failure/ischemic disease (DIAMOND trials). While primarily indicated for AF, it is a recognized second-line option for VT suppression in patients with severe LV dysfunction who cannot take amiodarone or sotalol.\n\nThe item is logically sound and medically accurate for board-exam purposes.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Valid (V). Verdict: Keyed answer (D) is the correct best answer. The vignette describes a patient with peripartum cardiomyopathy and HFrEF (LVEF 30%) at 36 weeks gestation. The question asks which medication must be avoided. Sacubitril/valsartan (Option D) contains valsartan, an Angiotensin Receptor Blocker (ARB). ARBs (and ACE inhibitors) are strictly contraindicated in pregnancy, particularly in the second and third trimesters, due to severe fetotoxicity (renal failure, oligohydramnios, calvarial defects). Options B and C (Hydralazine and Isosorbide dinitrate) represent the standard alternative vasodilator regimen for heart failure in pregnancy. Digoxin (A) and Metoprolol (E) are widely accepted for use in pregnancy when indicated. The distinction is clear, medically accurate, and aligns with major guidelines (e.g., ESC, ACOG).\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Valid (V). Verdict: Keyed answer (D) is the correct best answer. The vignette describes a patient with peripartum cardiomyopathy and HFrEF (LVEF 30%) at 36 weeks gestation. The question asks which medication must be avoided. Sacubitril/valsartan (Option D) contains valsartan, an Angiotensin Receptor Blocker (ARB). ARBs (and ACE inhibitors) are strictly contraindicated in pregnancy, particularly in the second and third trimesters, due to severe fetotoxicity (renal failure, oligohydramnios, calvarial defects). Options B and C (Hydralazine and Isosorbide dinitrate) represent the standard alternative vasodilator regimen for heart failure in pregnancy. Digoxin (A) and Metoprolol (E) are widely accepted for use in pregnancy when indicated. The distinction is clear, medically accurate, and aligns with major guidelines (e.g., ESC, ACOG).", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a 5-year-old girl with cerebellar atrophy, ataxia, and nystagmus, which are pathognomonic for Ataxia-Telangiectasia (A-T). Consequently, the intended key is Option E (ATM gene mutation). However, the stem states that flow cytometry shows \\\"absent B cells.\\\" This is medically inaccurate for A-T. Patients with A-T typically have normal or elevated numbers of B cells (specifically naive B cells), although they exhibit defects in class switching and memory B cell formation (leading to the low IgA/IgG described). \\\"Absent B cells\\\" is the hallmark finding of Agammaglobulinemia (e.g., XLA) or T-B- SCID (e.g., RAG deficiency). While Option A (BTK) fits the \\\"absent B cells\\\" finding, it is X-linked (unlikely in a female) and does not cause ataxia. Option D (RAG1) causes absent B cells but presents as SCID in infancy without cerebellar atrophy. The item contains a logical contradiction: the neurological phenotype confirms A-T, while the immunophenotype (absent B cells) rules it out. The explanation confirms the author incorrectly believes A-T presents with absent B cells.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a 5-year-old girl with cerebellar atrophy, ataxia, and nystagmus, which are pathognomonic for Ataxia-Telangiectasia (A-T). Consequently, the intended key is Option E (ATM gene mutation). However, the stem states that flow cytometry shows \"absent B cells.\" This is medically inaccurate for A-T. Patients with A-T typically have normal or elevated numbers of B cells (specifically naive B cells), although they exhibit defects in class switching and memory B cell formation (leading to the low IgA/IgG described). \"Absent B cells\" is the hallmark finding of Agammaglobulinemia (e.g., XLA) or T-B- SCID (e.g., RAG deficiency). While Option A (BTK) fits the \"absent B cells\" finding, it is X-linked (unlikely in a female) and does not cause ataxia. Option D (RAG1) causes absent B cells but presents as SCID in infancy without cerebellar atrophy. The item contains a logical contradiction: the neurological phenotype confirms A-T, while the immunophenotype (absent B cells) rules it out. The explanation confirms the author incorrectly believes A-T presents with absent B cells.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with recurrent hepatic encephalopathy (HE) refractory to standard maximal medical therapy (lactulose and rifaximin), with TIPS contraindicated. The question asks for the intervention with the \\\"strongest evidence\\\" for reducing recurrence. The keyed answer, Polyethylene glycol (PEG), has demonstrated efficacy superior to lactulose for the rapid resolution of *acute* HE in randomized trials (e.g., Rahimi et al., 2014). However, there is no robust evidence base or guideline recommendation supporting daily PEG as a superior prophylactic agent for *preventing recurrence* compared to standard care or other adjuncts. In contrast, Option E (Branch-chain amino acids) is explicitly recommended by EASL guidelines for patients with cirrhosis and HE, and Cochrane reviews confirm a beneficial effect on HE manifestations. The provided rationale incorrectly extrapolates acute efficacy data to chronic maintenance and inaccurately dismisses the evidence for BCAAs. Consequently, Option E is the most medically defensible answer among the choices, making the item miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with recurrent hepatic encephalopathy (HE) refractory to standard maximal medical therapy (lactulose and rifaximin), with TIPS contraindicated. The question asks for the intervention with the \"strongest evidence\" for reducing recurrence. The keyed answer, Polyethylene glycol (PEG), has demonstrated efficacy superior to lactulose for the rapid resolution of *acute* HE in randomized trials (e.g., Rahimi et al., 2014). However, there is no robust evidence base or guideline recommendation supporting daily PEG as a superior prophylactic agent for *preventing recurrence* compared to standard care or other adjuncts. In contrast, Option E (Branch-chain amino acids) is explicitly recommended by EASL guidelines for patients with cirrhosis and HE, and Cochrane reviews confirm a beneficial effect on HE manifestations. The provided rationale incorrectly extrapolates acute efficacy data to chronic maintenance and inaccurately dismisses the evidence for BCAAs. Consequently, Option E is the most medically defensible answer among the choices, making the item miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible). The item contains major physiological and medical inaccuracies. The patient presents with acute decompensated heart failure (ADHF) and an LVEF of 20%. In this clinical state, NT-proBNP is universally elevated due to significant myocardial wall stress, regardless of the specific toxic etiology (trastuzumab vs. anthracycline). Therefore, the keyed answer (A), which posits 'Normal NT-proBNP,' is physiologically impossible in the context of the stem. Furthermore, the provided rationale contradicts standard cardio-oncology teaching. Anthracycline toxicity (Type I) involves myocyte necrosis and is classically associated with elevated troponin, whereas trastuzumab toxicity (Type II) involves cellular dysfunction often without frank necrosis, making troponin less consistently elevated than in anthracycline toxicity. There is no specific biomarker profile listed that reliably differentiates these two conditions in the acute setting; differentiation is primarily based on exposure history and reversibility. Because the keyed answer contradicts the physiology of heart failure described in the stem, no option is defensible.\",\"medical_accuracy_score\":\"1\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible). The item contains major physiological and medical inaccuracies. The patient presents with acute decompensated heart failure (ADHF) and an LVEF of 20%. In this clinical state, NT-proBNP is universally elevated due to significant myocardial wall stress, regardless of the specific toxic etiology (trastuzumab vs. anthracycline). Therefore, the keyed answer (A), which posits 'Normal NT-proBNP,' is physiologically impossible in the context of the stem. Furthermore, the provided rationale contradicts standard cardio-oncology teaching. Anthracycline toxicity (Type I) involves myocyte necrosis and is classically associated with elevated troponin, whereas trastuzumab toxicity (Type II) involves cellular dysfunction often without frank necrosis, making troponin less consistently elevated than in anthracycline toxicity. There is no specific biomarker profile listed that reliably differentiates these two conditions in the acute setting; differentiation is primarily based on exposure history and reversibility. Because the keyed answer contradicts the physiology of heart failure described in the stem, no option is defensible.", "medical_accuracy_score": 1, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 1}]